SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical ...
RANCHO CORDOVA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL), a non-profit, biotech focused on ...
SK pharmteco, SK Group's contract development and manufacturing organization (CDMO) for pharmaceuticals, is moving to spin ...
RANCHO CORDOVA, Calif., May 05, 2026 (GLOBE NEWSWIRE)-- SK pharmteco announced today that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based ...
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE)-- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while ...
RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE)-- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This ...
SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced that David Lowndes will be appointed as Chief Operating Officer. David ...
RANCHO CORDOVA, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the ...
SK Pharmteco, a contract development manufacturing organization affiliated with SK Group, is considering selling its manufacturing plant in Virginia to Danish pharmaceuticals company Novo Nordisk, ...
SK's CDMO unit expects its 2021 sales to reach all-time high of $740 million SK Pharmteco, SK Inc.’s subsidiary of contract development and manufacturing organization, is planning for a pre-initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results